Updated results from the CheckMate 274 trial support the use of adjuvant nivolumab as standard care for high-risk muscle-invasive urothelial carcinoma, according to researchers.

It uses electromagnetic waves to target tumors and is available to patients for whom first- and second-line treatments have ...

Erik Nelson is a professor of Molecular and Integrative Physiology at the University of Illinois. Nelson also leads the ...